Literature DB >> 15804151

Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery.

Shu Li1, Hongwen Ji, Jing Lin, Eric Lenehan, Bingyang Ji, Jinping Liu, Jin Liu, Cun Long, Terry A Crane.   

Abstract

Acute preoperative plateletpheresis (APP), cell salvage (CS) technique, and the use of aprotinin have been individually reported to be effective in reducing blood loss and blood component transfusion while improving hematological profiles in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). In this prospective randomized clinical study, the efficacy of these combined approaches on reducing blood loss and transfusion requirements was evaluated. Seventy patients undergoing primary coronary artery bypass grafting (CABG) were randomly divided into four groups: a control group (group I, n = 10) did not receive any of the previously mentioned approaches. An APP and CS group (group II, n = 20) experienced APP in which preoperative platelet-rich plasma was collected and reinfused after reversal of heparin, along with the cell salvage technique throughout surgery. The third group (group III, n = 22) received aprotinin in which 5,000,000 KIU Trasylol was applied during surgery, and a combination group (group IV, n = 18) was treated with all three approaches, i.e., APP, CS, and aprotinin. Compared with group I (896+/-278 mL), the postoperative total blood loss was significantly reduced in groups II, III, and IV (468+/-136, 388+/-122, 202+/-81 mL, respectively, p < 0.05). The requirements of packed red blood cells in the three approached groups (153+/-63, 105+/-178, 0+/-0 mL, respectively) also were reduced when compared with group I (343+/-118 mL, p < 0.05). In group I, six patients (6/10) received fresh-frozen plasma and three patients (3/10) received platelet transfusion, whereas no patients in the other three groups required fresh-frozen plasma and platelet. In conclusion, both plateletpheresis concomitant with cell salvage and aprotinin contribute to the improvement of postoperative hemostasis, and the combination of these two approaches could minimize postoperative blood loss and requirement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804151      PMCID: PMC4680807     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  28 in total

1.  Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.

Authors:  Peter K Smith; Santanu K Datta; Lawrence H Muhlbaier; Gregory Samsa; Andrea Nadel; Joseph Lipscomb
Journal:  Ann Thorac Surg       Date:  2004-02       Impact factor: 4.330

2.  Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy.

Authors:  M Lass; A Welz; M Kochs; G Mayer; M Schwandt; A Hannekum
Journal:  Eur J Cardiothorac Surg       Date:  1995       Impact factor: 4.191

Review 3.  Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid.

Authors:  D Royston
Journal:  Int Anesthesiol Clin       Date:  1995

4.  Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.

Authors:  T B Spanier; J M Chen; M C Oz; N M Edwards; W Kisiel; D M Stern; E A Rose; A M Schmidt
Journal:  J Thorac Cardiovasc Surg       Date:  1998-11       Impact factor: 5.209

5.  Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass.

Authors:  Y J Gu; R J Huyzen; W van Oeveren
Journal:  Anesth Analg       Date:  1996-08       Impact factor: 5.108

6.  Complement and contact activation during cardiovascular operations in infants.

Authors:  J Sonntag; I Dähnert; B Stiller; R Hetzer; P E Lange
Journal:  Ann Thorac Surg       Date:  1998-02       Impact factor: 4.330

7.  A comparison of Cell Saver versus ultrafilter during coronary artery bypass operations.

Authors:  R H Breyer; R M Engelman; J A Rousou; S A Lemeshow
Journal:  J Thorac Cardiovasc Surg       Date:  1985-11       Impact factor: 5.209

8.  Autologous platelet-rich plasma in cardiac surgery: aesthetics versus virtue.

Authors:  G P Gravlee
Journal:  J Cardiothorac Vasc Anesth       Date:  1993-02       Impact factor: 2.628

9.  Heparin neutralization by recombinant platelet factor 4 and protamine.

Authors:  J H Levy; J G Cormack; A Morales
Journal:  Anesth Analg       Date:  1995-07       Impact factor: 5.108

10.  Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study.

Authors:  R Mohr; D A Goor; A Lusky; J Lavee
Journal:  Circulation       Date:  1992-11       Impact factor: 29.690

View more
  2 in total

Review 1.  A meta-analysis of platelet gel for prevention of sternal wound infections following cardiac surgery.

Authors:  Bilal H Kirmani; Siôn G Jones; Subir Datta; Edward K Mclaughlin; Andreas J Hoschtitzky
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

Review 2.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.